News

Curaxin CBLC102 has been used in the past to treat malaria and has demonstrated efficacy in vitro, in animal models, and in live tumors removed from patients. Initial

The contract will fund AVI’s development of antisense therapeutics to treat the effects of ebola, marburg and junin hemorrhagic viruses, which are seen as biological warfare and bioterrorism

Preliminary data received did confirm that the drug is dose responsive, produces a statistically significant reduction in bad (LDL) cholesterol and has maintained an excellent safety profile. However,

Avandia (rosiglitazone) reduced the risk of failure by 32% compared to metformin and 63% compared to glyburide at five years. Rosiglitazone was also more effective than metformin or

The phase III trials investigated the efficacy and safety of oral lacosamide as adjunctive therapy in adults with uncontrolled partial seizures. The percent reduction in seizure frequency over

Lennox-Gastaut syndrome is one of the most severe forms of childhood epilepsy. This form of catastrophic epilepsy, characterized by several seizure types, represents up to 10% of all

“The progression of this therapeutic candidate is an example of Xanthus' commitment to the development of products that address hematological malignancies that pose an unmet medical need,” stated

Regadenoson is a selective A2A-adenosine receptor agonist for potential use as a pharmacologic stress agent in myocardial perfusion imaging (MPI) studies. A prior identically designed phase III study,

The phase III trial evaluated Nexavar when administered in combination with a standard dosing schedule of the chemotherapy drugs, carboplatin and paclitaxel. The study was designed to measure